Detalhe da pesquisa
1.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Ann Hematol
; 100(2): 437-443, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392702
2.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Cancer
; 125(5): 750-760, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561775
3.
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Eur J Haematol
; 98(3): 289-295, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27893171
4.
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Blood Cancer J
; 11(6): 106, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083504
5.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
; 7(6): e456-e468, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359506
6.
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Expert Opin Drug Metab Toxicol
; 14(1): 91-99, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29235380
7.
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Front Immunol
; 9: 2749, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30538704
8.
Melphalan hydrochloride for the treatment of multiple myeloma.
Expert Opin Pharmacother
; 18(11): 1127-1136, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28658983
9.
Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
Expert Opin Drug Discov
; 9(8): 931-43, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24877566
10.
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Expert Opin Biol Ther
; 14(8): 1127-44, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24749510
11.
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Expert Opin Investig Drugs
; 23(9): 1193-209, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24905450
12.
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
Expert Opin Drug Metab Toxicol
; 9(11): 1517-27, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23961770
13.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Leukemia
; 32(8): 1803-1807, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29479061